|Title||Direct cloning and refactoring of a silent lipopeptide biosynthetic gene cluster yields the antibiotic taromycin A|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Yamanaka K, Reynolds K.A, Kersten RD, Ryan K.S, Gonzalez D.J, Nizet V., Dorrestein PC, Moore BS|
|Journal||Proceedings of the National Academy of Sciences of the United States of America|
|Type of Article||Article|
|Keywords||biosynthesis; conjugal transfer; daptomycin biosynthesis; DNA; drug discovery; escherichia-coli; genome mining; heterologous expression; natural-product discovery; plasmid; saccharomyces-cerevisiae; streptomyces-coelicolor; transformation-associated recombination|
Recent developments in next-generation sequencing technologies have brought recognition of microbial genomes as a rich resource for novel natural product discovery. However, owing to the scarcity of efficient procedures to connect genes to molecules, only a small fraction of secondary metabolomes have been investigated to date. Transformation-associated recombination (TAR) cloning takes advantage of the natural in vivo homologous recombination of Saccharomyces cerevisiae to directly capture large genomic loci. Here we report a TAR-based genetic platform that allows us to directly clone, refactor, and heterologously express a silent biosynthetic pathway to yield a new antibiotic. With this method, which involves regulatory gene remodeling, we successfully expressed a 67-kb nonribosomal peptide synthetase biosynthetic gene cluster from the marine actinomycete Saccharomonospora sp. CNQ-490 and produced the dichlorinated lipopeptide antibiotic taromycin A in the model expression host Streptomyces coelicolor. The taromycin gene cluster (tar) is highly similar to the clinically approved antibiotic daptomycin from Streptomyces roseosporus, but has notable structural differences in three amino acid residues and the lipid side chain. With the activation of the tar gene cluster and production of taromycin A, this study highlights a unique "plug-and-play" approach to efficiently gaining access to orphan pathways that may open avenues for novel natural product discoveries and drug development.